Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Hikma Pharmaceuticals Usa Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, showing that every pending matter is being reviewed by a different official. The workload is spread across 3 distinct art units, which suggests technical variety within the company's pharmaceutical interests. This distribution requires the applicant to monitor different examination styles simultaneously while maintaining a consistent overall strategy for the portfolio.
SOROUSH, LAYLA is identified as the busiest examiner for this portfolio. This examiner is currently handling 1 busiest examiner pending office action. The remaining actions are distributed among the other examiners. This distribution across multiple examiners and 3 distinct art units may require the applicant to coordinate different prosecution strategies. Practitioners should be prepared to address the specific concerns of separate officials, even though the technical focus remains within the pharmaceutical field. The presence of multiple art units indicates that the company's applications are classified under different categories, each with its own set of prior art and examination standards.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| ROBERTS, LEZAH | 1 | 48.6% | +35.7% |
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598526 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | SOROUSH, LAYLA | 182d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598526 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | SOROUSH, LAYLA | 182d overdue |
| 18543158 | Buffered Lidocaine Injectable Formulations and Methods for Making Same | ROBERTS, LEZAH | 98d overdue |
| 18453360 | EPINEPHRINE SPRAY FORMULATIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1612 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18598526 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | SOROUSH, LAYLA | 1622 | §102§103Other | Non-Final OA | 182d overdue | Pending | Mar 07, 2024 |
| 18543158 | Buffered Lidocaine Injectable Formulations and Methods for Making Same | ROBERTS, LEZAH | 1612 | §103 | Final Rejection | 98d overdue | Pending | Dec 18, 2023 |
| 18453360 | EPINEPHRINE SPRAY FORMULATIONS | HUI, SAN MING R | 1627 | DP | Final Rejection | — | Pending | Aug 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHikma Pharmaceuticals Usa Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Layla Soroush has the most, with 1 of Hikma Pharmaceuticals Usa Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
